Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HYDROSERPINE PLUS (R-H-H) vs ALDORIL D30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water. Reserpine depletes catecholamines from peripheral sympathetic nerve endings, reducing sympathetic tone. Hydralazine directly relaxes arteriolar smooth muscle, decreasing systemic vascular resistance.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
Hypertension
Hypertension
1 tablet orally twice daily. Each tablet contains hydrochlorothiazide 25 mg, reserpine 0.125 mg, and hydralazine hydrochloride 25 mg.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
Hydroflumethiazide: 2-3 h; reserpine: 50-100 h (biphasic); hydralazine: 2-4 h (fast acetylators), 6-8 h (slow acetylators).
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Hydrochlorothiazide: Not metabolized, excreted unchanged in urine. Reserpine: Metabolized in the liver via hydrolysis and conjugation. Hydralazine: Acetylation in the liver via N-acetyltransferase (NAT2).
Methyldopa is metabolized by conjugation (catechol-O-methyltransferase) and hepatic sulfation; hydrochlorothiazide is not extensively metabolized and is excreted unchanged by the kidney.
Hydroflumethiazide: renal (50-65% unchanged); reserpine: renal (30%) and fecal (60%) as metabolites; hydralazine: renal (85% as metabolites, 10% unchanged).
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
Hydroflumethiazide: 70% (albumin); reserpine: 96%; hydralazine: 87% (albumin and alpha-1 acid glycoprotein).
Methyldopa: <10% bound to plasma proteins; hydrochlorothiazide: 40-68% bound to albumin.
Hydroflumethiazide: 3.6 L/kg; reserpine: 10-20 L/kg; hydralazine: 1.6 L/kg (central) and 2.7 L/kg (total).
Methyldopa: Vd 0.2-0.3 L/kg (distributes into tissues, crosses placenta); hydrochlorothiazide: Vd 0.75-1.5 L/kg (extensively distributed, does not cross blood-brain barrier significantly).
Oral: hydroflumethiazide 70-75%; reserpine 50-60%; hydralazine 30-50% (first-pass metabolism).
Oral bioavailability of methyldopa is approximately 25% (variable, influenced by gut metabolism); hydrochlorothiazide bioavailability is 65-75%.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). For Cr Cl 30-50 m L/min: reduce dose to 1 tablet orally once daily; monitor electrolytes. No adjustment needed for Cr Cl >50 m L/min.
GFR 30-60 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For Child-Pugh class A or B: use with caution; reduce dose to 1 tablet orally once daily and monitor for encephalopathy.
Child-Pugh Class B or C: contraindicated; use not recommended.
Not recommended for pediatric use due to lack of safety and efficacy data.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Start with 1 tablet orally once daily; titrate slowly. Monitor for orthostatic hypotension, electrolyte imbalances, and CNS effects. Avoid use in patients with depression.
Start with lowest dose; monitor for hypotension, electrolyte imbalance, and CNS effects; consider reduced initial dose.
Reserpine: May cause mental depression, especially in patients with a history of depression. Discontinue at first signs of depression.
None
Hydrochlorothiazide: Electrolyte imbalance, hyperglycemia, hyperuricemia, lupus exacerbation. Reserpine: Mental depression, peptic ulcer, bradycardia. Hydralazine: Drug-induced lupus, tachycardia, myocardial ischemia, peripheral neuritis.
May cause hemolytic anemia, liver disorders, positive Coombs test, sedation, depression, and hypersensitivity reactions. Hydrochlorothiazide may cause electrolyte imbalance, hyperuricemia, photosensitivity, and exacerbation of systemic lupus erythematosus. Use with caution in renal impairment, hepatic disease, and in patients with a history of drug-induced hemolytic anemia.
Reserpine: Hypersensitivity, history of depression, active peptic ulcer, ulcerative colitis, pheochromocytoma. Hydralazine: Hypersensitivity, mitral valve rheumatic heart disease, coronary artery disease. Hydrochlorothiazide: Anuria, hypersensitivity to sulfonamides, severe renal failure.
Active hepatic disease, history of previous methyldopa therapy-associated liver disorders; anuria; hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamide-derived drugs.
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, spinach) due to the potassium-sparing effect of the combination? Note: Actually HYDROSERPINE PLUS contains hydrochlorothiazide which is potassium-wasting; reserpine and hydralazine do not affect potassium significantly. Thus, potassium supplementation may be needed; monitor potassium levels. Limit sodium intake to control blood pressure. Avoid tyramine-rich foods (e.g., aged cheeses, cured meats) due to reserpine's potential to cause hypertensive crisis? Reserpine is not a MAOI, but caution with high-tyramine foods is advised.
Food may decrease absorption of methyldopa. Avoid excessive intake of high-potassium foods (e.g., bananas, oranges) unless directed. Hydrochlorothiazide may cause potassium depletion; maintain adequate dietary potassium. Avoid natural licorice as it can worsen hypokalemia.
First trimester: Hydrochlorothiazide is associated with an increased risk of neural tube defects and oral clefts; reserpine may cause respiratory distress; hydralazine is not teratogenic in animal studies. Second and third trimesters: Hydrochlorothiazide may cause fetal electrolyte disturbances and thrombocytopenia; reserpine may cause neonatal bradycardia and hypotension; hydralazine may cause fetal hypotension and reflex tachycardia.
First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; possible fetal bradycardia and neonatal hypotension. Hydrochlorothiazide may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
Hydrochlorothiazide is excreted in breast milk in low concentrations (M/P ratio 0.6); reserpine is excreted (M/P ratio unknown, but may cause galactorrhea and infant sedation); hydralazine is excreted in low amounts (M/P ratio not well defined). Theoretical risk of hypotensive effects in infants. Caution recommended.
Methyldopa is excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Hydrochlorothiazide is excreted in minimal amounts; may suppress lactation. Consider risks versus benefits.
No specific dose adjustments have been established for the combination; however, increased plasma volume and renal clearance in pregnancy may reduce efficacy, potentially requiring dose increase or alternative therapy. Individualize based on blood pressure response and avoid volume depletion.
Methyldopa: Pregnancy-induced plasma volume expansion may require dose titration; monitor blood pressure and adjust accordingly. Hydrochlorothiazide: Often avoided in pregnancy due to volume depletion risks; if used, monitor electrolytes and renal function, no pharmacokinetic data necessitate routine dose adjustment.
Hydralazine and hydrochlorothiazide can cause lupus-like syndrome; monitor for arthralgias, rash, and fever. Reserpine depletes catecholamines, leading to potential sedation and depression; use with caution in patients with history of mood disorders. Check serum potassium and uric acid levels due to thiazide component.
ALDORIL D30 combines methyldopa (central alpha-2 agonist) and hydrochlorothiazide (thiazide diuretic). Monitor for orthostatic hypotension, especially at initiation. Taper not needed for methyldopa but discontinue if fever or liver dysfunction occurs. Interferes with urinary catecholamine measurements (false elevation). Hydrochlorothiazide may cause hyponatremia, hypokalemia, and hyperglycemia; check electrolytes and glucose periodically.
Take this medication exactly as prescribed; do not skip doses or double up.,Rise slowly from sitting or lying down to prevent dizziness.,Avoid driving or operating machinery until you know how this drug affects you.,Report any unusual weight gain, swelling, or shortness of breath.,Contact your doctor if you experience joint pain, fever, or rash.,Do not stop taking this medicine abruptly; it may cause blood pressure to rise.,Limit alcohol consumption as it can increase dizziness and drowsiness.
Take exactly as prescribed, preferably with food to reduce stomach upset.,Rise slowly from sitting or lying down to prevent dizziness.,This drug may make you drowsy; avoid driving or operating machinery until you know how it affects you.,Report fever, unexplained fatigue, jaundice, or dark urine immediately.,Weigh yourself daily and report rapid weight gain or swelling.,Limit alcohol intake as it can increase side effects.,Do not use salt substitutes containing potassium without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HYDROSERPINE PLUS (R-H-H) vs ALDORIL D30, answered by our medical review team.
HYDROSERPINE PLUS (R-H-H) is a Antihypertensive Combination that works by Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water. Reserpine depletes catecholamines from peripheral sympathetic nerve endings, reducing sympathetic tone. Hydralazine directly relaxes arteriolar smooth muscle, decreasing systemic vascular resistance.. ALDORIL D30 is a Antihypertensive Combination that works by Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HYDROSERPINE PLUS (R-H-H) and ALDORIL D30 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HYDROSERPINE PLUS (R-H-H) is: 1 tablet orally twice daily. Each tablet contains hydrochlorothiazide 25 mg, reserpine 0.125 mg, and hydralazine hydrochloride 25 mg.. The standard adult dose of ALDORIL D30 is: Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HYDROSERPINE PLUS (R-H-H) and ALDORIL D30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HYDROSERPINE PLUS (R-H-H) is classified as Category C. First trimester: Hydrochlorothiazide is associated with an increased risk of neural tube defects and oral clefts; reserpine may cause respiratory distress; hydralazine is not terat. ALDORIL D30 is classified as Category C. First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.